V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005353 | 330013141 | 1.76 | 0 | Palliative (P) | 2017-07-29 | 2017-07-29 | CETUXIMAB + CISPLATIN + FU | N | N | 330023088 | DOXORUBICIN + IFOSFAMIDE |
| 330005354 | 330013314 | 1.49 | 46.9 | Adjuvant (A) | 2017-12-02 | 2017-12-07 | FLUOROURACIL + MITOMYCIN + RT | 2 | N | 330023095 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330005355 | 330002558 | 1.74 | 75 | Curative (C) | 2013-09-30 | 2013-10-03 | BEP 5 Day | 02 | N | 330023101 | CTD |
| 330005356 | 330002558 | 1.79 | 28 | Palliative (P) | 2016-07-11 | 2016-07-16 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | 330023101 | VEPEMB |
| 330005357 | 330002558 | 1.68 | 53 | Curative (C) | 2017-12-24 | 2017-12-24 | FLUDARABINE | Y | N | 330023101 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330005358 | 330002558 | 1.66 | 78.9 | null | 2014-05-18 | 2015-03-06 | Bendamustine +/- Prednisolone | N | N | 330023101 | IDARUBICIN |
| 330005359 | 330002558 | 1.77 | 81.5 | Curative (C) | 2017-07-17 | 2017-07-17 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330023101 | CTD |
| 330005360 | 330002558 | 1.74 | 66.9 | Palliative (P) | 2014-05-13 | 2014-05-18 | RCD TRIAL | 2 | Y | 330023101 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330005361 | 330002559 | 1.56 | 89.3 | Curative (C) | 2015-10-05 | 2015-10-06 | Temozolomide 150mg/m2 | 02 | N | 330023130 | CHOP R |
| 330005362 | 330007406 | 1.64 | null | Not known (9) | 2016-04-28 | 2016-05-01 | ALL UKALL2011 Ind B Sht Dex (PAsp) | 1 | N | 330023138 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 330005363 | 330007406 | 1.74 | 73.5 | Palliative (P) | 2017-11-20 | 2017-11-23 | Topotecan (intravenous) | N | N | 330023138 | NIVOLUMAB |
| 330005364 | 330007406 | null | null | null | null | 2018-03-11 | OCTREOTIDE | null | null | 330023138 | CARBOPLATIN + RT |
| 330005365 | 330002560 | 1.77 | 75 | Adjuvant (A) | 2016-04-23 | 2016-04-23 | CHLORAMBUCIL + RITUXIMAB | N | N | 330023149 | CHOP R |
| 330005366 | 330002561 | null | 69.1 | Curative (C) | 2018-10-01 | 2018-10-01 | CISPLATIN + CYCLO + DOXORUBICIN | N | null | 330023152 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 330005367 | 330002562 | 1.83 | 96 | null | 2013-07-19 | 2013-07-30 | ALL UKALL2011 Ind A Sht Dex (PAsp) | N | N | 330023156 | CHOP R |
| 330005368 | 330002563 | 1.71 | 0 | Palliative (P) | 2016-02-16 | 2016-05-01 | ATG + Busulfan + Fludarabine | 2 | N | 330023159 | ETOPOSIDE |
| 330005369 | 330002564 | 1.79 | 72.4 | Adjuvant (A) | 2013-05-22 | 2013-05-25 | AML18 PILOT TRIAL | 02 | N | 330023161 | MITOTANE |
| 330005370 | 330002565 | 1.67 | 73 | Curative (C) | 2016-06-20 | 2016-06-20 | TCF | 02 | null | 330023162 | METHOTREXATE HIGH DOSE |
| 330005371 | 330002565 | 1.57 | 41.6 | Curative (C) | null | 2013-03-31 | STS Rhabdomyosarcoma RMS 2005 IVA | null | null | 330023162 | SUNITINIB |
| 330005374 | 330002567 | 1.7 | 44.6 | Curative (C) | 2016-02-13 | 2016-03-09 | Chlorambucil | 2 | N | 330023185 | GDP |
| 330005375 | 330002568 | null | null | Palliative (P) | 2016-06-01 | 2016-06-04 | CHOEP | N | N | 330023187 | IMATINIB |
| 330005376 | 330007409 | 1.65 | 102.7 | Adjuvant (A) | 2014-06-03 | 2014-06-10 | Cyclophosphamide + Topotecan | N | N | 330023188 | CHLORAMBUCIL |
| 330005377 | 330007409 | 1.67 | 49.3 | Curative (C) | 2015-02-26 | 2015-06-04 | Mifamurtide weeks 1-12 | N | N | 330023188 | HYDROXYCARBAMIDE |
| 330005378 | 330007409 | 1.9 | 92 | Palliative (P) | 2015-05-20 | 2015-05-26 | Etoposide oral | N | N | 330023188 | CVD |
| 330005379 | 330007409 | 0 | 56.7 | Curative (C) | 2015-04-19 | 2015-04-21 | Temozolomide + RT | 02 | N | 330023188 | PEMBROLIZUMAB |
| 330005380 | 330002569 | 1.69 | 73.5 | Curative (C) | 2013-10-25 | 2017-11-21 | EpSSG NRSTS 2005 | N | N | 330023236 | CARBOPLATIN + PEMETREXED |
| 330005381 | 330002570 | 1.55 | 74.65 | Palliative (P) | 2015-05-09 | 2015-05-13 | Carboplatin + Vinorelbine IV &PO D8 | 02 | N | 330023238 | MITOTANE |
| 330005382 | 330002571 | 1.86 | 49.1 | Disease modification (D) | 2017-02-20 | 2017-02-24 | Aldesleukin | Y | N | 330023240 | ADE |
| 330005383 | 330002571 | 1.72 | 49 | Palliative (P) | 2015-08-03 | 2015-08-03 | CARBOPLATIN + RT | 02 | N | 330023240 | CVD + LENALIDOMIDE |
| 330005384 | 330002572 | 0 | 66 | Palliative (P) | 2017-11-26 | 2017-11-27 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 330023245 | CYTARABINE |
| 330005385 | 330002573 | 1.82 | 83.3 | Curative (C) | 2017-07-09 | 2017-11-12 | VAC | 02 | N | 330023247 | FLUOROURACIL + MITOMYCIN + RT |
| 330005386 | 330002573 | 1.64 | 99.3 | Curative (C) | 2014-11-03 | 2014-11-12 | VAC | N | N | 330023247 | VIDE |
| 330005387 | 330002574 | 1.72 | 88.4 | Disease modification (D) | 2016-09-10 | 2016-09-11 | Methotrexate Intrathecal (any age) | null | N | 330023265 | CEV |
| 330005388 | 330002575 | 1.77 | 59.7 | Palliative (P) | 2017-05-19 | 2017-05-19 | Chlorambucil + Pred + Rituximab | 2 | N | 330023268 | CAPECITABINE + CISPLATIN |
| 330005389 | 330002576 | 1.6 | 48.1 | Palliative (P) | 2017-09-16 | 2017-09-26 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330023274 | HYDROXYCARBAMIDE |
| 330005390 | 330002576 | 1.72 | 8.4 | Disease modification (D) | 2018-05-06 | 2018-05-07 | EOX | N | N | 330023274 | AZACITIDINE |
| 330005391 | 330002576 | 0 | 65.3 | Curative (C) | 2013-01-10 | 2013-01-17 | Methotrexate + Folinic acid | N | N | 330023274 | IRINOTECAN + TEMOZOLOMIDE |
| 330005392 | 330002577 | 1.91 | 49 | Disease modification (D) | 2013-09-25 | 2013-11-02 | FLAG + Idarubicin | N | N | 330023305 | AML17 TRIAL |
| 330005393 | 330002578 | 0 | 77.6 | Palliative (P) | 2012-11-16 | 2012-11-17 | BEP 5 Day | N | N | 330023306 | PACLITAXEL |
| 330005394 | 330007413 | 1.67 | 0 | Curative (C) | 2014-05-28 | 2014-06-15 | AML Interim Guidelines FLAG-Ida | N | N | 330023308 | ECARBOX |
| 330005395 | 330002579 | 1.66 | 0 | Palliative (P) | 2013-01-22 | 2013-01-23 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | N | 330023310 | CHLORAMBUCIL + RITUXIMAB |
| 330005396 | 330002580 | null | null | Palliative (P) | 2014-11-22 | 2014-11-22 | Cisplatin + Docetaxel | 02 | null | 330023311 | MIDOSTAURIN |
| 330005397 | 330002580 | 1.71 | 68.999 | Curative (C) | 2016-02-12 | 2016-02-12 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 330023311 | BEP |
| 330005398 | 330010025 | 1.78 | 68.2 | Palliative (P) | 2013-03-17 | 2013-03-25 | Mitotane 2g | 02 | N | 330023317 | AZACITIDINE |
| 330005399 | 330010025 | 0 | 96.5 | Curative (C) | null | 2015-12-26 | Docetaxel | null | null | 330023317 | AML19 TRIAL |
| 330005400 | 330002581 | 0.86 | null | Curative (C) | null | 2017-10-31 | FLAG | null | null | 330023321 | CISPLATIN + FLUOROURACIL + RT |
| 330005401 | 330002581 | 1.65 | 61 | Palliative (P) | 2016-02-17 | 2016-02-24 | Docetaxel 100mg/m2 (21 day) | N | N | 330023321 | CHLORAMBUCIL + RITUXIMAB |
| 330005402 | 330002581 | 1.7 | null | null | 2015-06-11 | 2015-06-27 | CHOP R - 21 days | N | N | 330023321 | UKALL2011 |
| 330005403 | 330002581 | 1.83 | 95 | Curative (C) | null | 2016-10-07 | CHLORAMBUCIL + OFATUMUMAB | 02 | null | 330023321 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330005404 | 330012268 | 1.66 | 106.7 | Neo-adjuvant (N) | 2014-08-13 | 2014-08-24 | FLUOROURACIL + MITOMYCIN | N | N | 330023334 | HYDROXYCARBAMIDE |